Showing 2051-2060 of 2526 results for "".
- Discovery of a New Drug for Diabetic Retinopathyhttps://modernod.com/news/discovery-of-a-new-drug-for-diabetic-retinopathy/2478858/A potentially effective treatment for diabetic retinopathy has been developed by an Université de Montréal (UdeM) scientist and investigator at Maisonneuve-Rosemont Hospital Research Centre (MRH-RC). Working with research scientist Pam Tsuruda of the
- Medicom Healthcare Signs Asset Purchase Agreement of Bimatoprost 0.3 mg/mL, 3mlhttps://modernod.com/news/medicom-healthcare-signs-asset-purchase-agreement-of-bimatoprost-0-3-mg-ml-3ml/2478852/Medicom Healthcare and Famar Health Care Services Madrid have announced the signing of an Asset Purchase Agreement (APA) for the acquisition by Medicom of the pharmaceutical dossier of Bimatorost 0.3 mg/mL, 3ml, preservative free eye drop solution, developed by Famar R&D. Under this agreement
- Palatin Technologies Announces Filing of International Patent Application for Lead Compound for Dry Eye Diseasehttps://modernod.com/news/palatin-technologies-announces-filing-of-international-patent-application-for-lead-compound-for-dry-eye-disease/2478853/Palatin Technologies announced the filing of an international patent application under the Patent Cooperation Treaty (PCT) directed to the composition of PL9643 and a related family of melanocortin agonist peptides. Palatin recently reported positive results in its phase 2 study of PL9643
- Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of Covaxin in the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/2478849/Ocugen and Bharat Biotech announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s Covaxin, an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Under th
- Early Data Find AstraZeneca’s COVID-19 Vaccine Effective Against Fast-Spreading UK Strainhttps://modernod.com/news/early-data-find-astrazenecas-covid-19-vaccine-effective-against-fast-spreading-uk-strain/2478839/A preliminary analysis suggests that AstraZeneca’s AZD1222 vaccine is effective against COVID-19 caused by the highly-transmissible UK variant, according to a statement Friday by its partners at the University of Oxford. The findings, which are not peer-reviewed and were released as a prepr
- GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primateshttps://modernod.com/news/gensight-biologics-announces-the-publication-in-communications-biology-of-the-proof-of-concept-for-gs030-drug-product-in-none28091human-primates/2478834/GenSight Biologics announced that the journal Communications Biology has published results from the study of GS030-Drug Product (GS030-DP) in non-human primates (NHP). The paper,* published in the January issue under the title “Optogenetic therapy: high spatiotemporal resolution and
- Johnson & Johnson Vision Receives FDA Approval For Tecnis Eyhance and Tecnis Eyhance Toric II Monofocal IOLshttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-next-generation-monofocal-intraocular-lens-tecnis-eyhance-and-tecnis-eyhance-toric-ii-iols/2478822/Johnson & Johnson Vision announced that the FDA has approved the Tecnis Eyhance and Tecnis Eyhance Toric II IOLs in the United States. The first implantation of Tecnis Eyhance IOL in the US will happen in Texas next week. <
- Alcon Canada Introduces the Clareon IOL with the AutonoMe Preloaded Intraocular Lens Delivery Systemhttps://modernod.com/news/alcon-canada-introduces-the-clareon-iol-with-the-autonome-preloaded-intraocular-lens-delivery-system/2478820/Alcon has announced a nationwide launch of the Clareon IOL with the AutonoMe delivery system in Canada. AutonoMe is an automated, disposable, preloaded IOL delivery system that enables precise delivery of the IOL into the capsular bag in patients undergoing cataract surgery, according to
- Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfoliohttps://modernod.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/Horizon Therapeutics and Viela Bio announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio common stock for $53 per share in cash, which represents a fully diluted equity value of approximately $3.05 b
- EU Authorizes AstraZeneca’s COVID-19 Vaccine Amid Supply Disputehttps://modernod.com/news/eu-authorizes-astrazenecas-covid-19-vaccine-amid-supply-dispute/2478816/The European Commission on Friday granted a conditional marketing authorization to AstraZeneca and the University of Oxford’s AZD1222 for people aged 18 years and older, making it the third COVID-19 vaccine authorized in the EU, following Pfizer and BioNTech’s vaccine Comirnaty, as we